Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24816160 | 0.86 | MAPT (0.50) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL19029863 | 0.84 | IRAK4 (0.43) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL11835695 | 0.75 | MAPT (0.53) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL25189536 | 0.74 | MAPT (0.48) | MAPTALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL29290889 | 0.72 | MAPT (0.43) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL25188728 | 0.72 | MAPT (0.46) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL22151076 | 0.71 | NPC1 (0.44) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL10702301 | 0.71 | MAPT (0.51) | MEN1KMT2AMAPTALDH1A1RAB9A | |
| SCHEMBL25189804 | 0.71 | MAPT (0.45) | MAPTALDH1A1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL18896263 | 0.71 | MAPT (0.66) | MEN1KMT2AMAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111465603-B | Triazolopyridines as gamma secretase modulators | 勃林格殷格翰国际有限公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11339161-B2 | Triazolo pyridines as modulators of gamma-secretase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-24 | — | — | US | disclosed |
| US-11339161-B2 | Triazolo pyridines as modulators of gamma-secretase | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-24 | — | — | US | disclosed |
| EP-3672971-B1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | BOEHRINGER INGELHEIM INT (DE) | 2021-07-14 | — | — | EP | disclosed |
| US-20210017173-A1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017173-A1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-01-21 | — | — | US | disclosed |
| CN-111465603-A | Triazolopyridines as gamma-secretase modulators | 勃林格殷格翰国际有限公司 | 2020-07-28 | — | — | CN | disclosed |
| EP-3672971-A1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | Boehringer Ingelheim International GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017173-A1 | TRIAZOLO PYRIDINES AS MODULATORS OF GAMMA-SECRETASE | BACE1, BACE2, APP | MEN1 3692/4885KMT2A 2843/4885MAPT 34/4885 |
| US-11339161-B2 | Triazolo pyridines as modulators of gamma-secretase | BACE1, BACE2, APP | MEN1 3692/4885KMT2A 2843/4885MAPT 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.